

Title (en)  
PHARMACEUTICAL COMPOSITION COMPRISING 1,2-NAPHTHOQUINONE DERIVATIVE FOR USE IN PREVENTING OR TREATING ACUTE MYELOID OR LYMPHOBLASTIC LEUKEMIA

Title (de)  
PHARMAZEUTISCHE ZUSAMMENSETZUNG ENTHALTEND EIN 1,2-NAPHTHOCHINONDERIVAT ZUR VERWENDUNG BEI DER VORBEUGUNG ODER BEHANDLUNG VON AKUTER MYELOISCHER ODER LYMPHOBLASTISCHER LEUKÄMIE

Title (fr)  
COMPOSITION PHARMACEUTIQUE COMPRENANT UN DÉRIVÉ DE 1,2-NAPHTHOQUINONE POUR UNE UTILISATION DANS LA PRÉVENTION OU LE TRAITEMENT DE LA LEUCÉMIE AIGUË MYÉLOÏDE OU LYMPHOBLASTIQUE

Publication  
**EP 3782620 B1 20231220 (EN)**

Application  
**EP 19784600 A 20190404**

Priority  
• KR 20180040913 A 20180409  
• KR 20180040884 A 20180409  
• KR 20180040895 A 20180409  
• KR 2019004001 W 20190404

Abstract (en)  
[origin: EP3782620A1] The present invention relates to a pharmaceutical composition for preventing or treating solid cancer and blood cancers such as acute leukemia and chronic leukemia, comprising a derivative compound of 1,2-naphthoquinone or a pharmaceutically acceptable salt thereof as an effective component. The derivative compound of 1,2-naphthoquinone is highly effective in killing cancer cells of various solid cancers, acute leukemia, and chronic leukemia, and thus can be beneficially used as a pharmaceutical composition for preventing or treating cancers, especially solid cancers, acute leukemia, and chronic leukemia.

IPC 8 full level  
**A61K 31/4184** (2006.01); **A61K 31/4192** (2006.01); **A61K 31/423** (2006.01); **A61K 31/428** (2006.01); **A61K 31/4439** (2006.01); **A61K 31/454** (2006.01); **A61K 31/4745** (2006.01); **A61K 31/5377** (2006.01); **A61P 35/00** (2006.01); **A61P 35/02** (2006.01); **C07D 263/60** (2006.01); **C07D 401/04** (2006.01); **C07D 405/04** (2006.01); **C07D 413/04** (2006.01); **C07D 417/04** (2006.01)

CPC (source: EP KR US)  
**A61K 31/4184** (2013.01 - KR US); **A61K 31/4192** (2013.01 - EP KR US); **A61K 31/423** (2013.01 - EP KR US); **A61K 31/428** (2013.01 - EP KR US); **A61K 31/4439** (2013.01 - EP); **A61K 31/454** (2013.01 - EP); **A61K 31/4745** (2013.01 - EP KR US); **A61K 31/5377** (2013.01 - EP); **A61P 35/00** (2017.12 - EP KR US); **A61P 35/02** (2017.12 - EP KR US); **C07D 263/60** (2013.01 - EP US); **C07D 401/04** (2013.01 - EP US); **C07D 405/04** (2013.01 - EP US); **C07D 413/04** (2013.01 - EP US); **C07D 417/04** (2013.01 - EP US)

Citation (examination)  
CARTER-COOPER BRANDON A ET AL: "Synthesis, characterization and antineoplastic activity of bis-aziridinyl dimeric naphthoquinone - A novel class of compounds with potent activity against acute myeloid leukemia cells", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM NL, vol. 27, no. 1, 17 November 2016 (2016-11-17), pages 6 - 10, XP029837684, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2016.11.045

Designated contracting state (EPC)  
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)  
**EP 3782620 A1 20210224**; **EP 3782620 A4 20211208**; **EP 3782620 B1 20231220**; CN 110709079 A 20200117; CN 110709079 B 20230912; JP 2020524133 A 20200813; JP 7007746 B2 20220125; KR 20190118119 A 20191017; US 11717511 B2 20230808; US 2021155596 A1 20210527; WO 2019198976 A1 20191017

DOCDB simple family (application)  
**EP 19784600 A 20190404**; CN 201980002563 A 20190404; JP 2019566065 A 20190404; KR 20190039775 A 20190404; KR 2019004001 W 20190404; US 201916618289 A 20190404